$0.62
-0.04 (-5.77%)
Open$0.68
Previous Close$0.66
Day High$0.68
Day Low$0.61
52W High$28.08
52W Low$1.07
Volume—
Avg Volume53.7K
Market Cap2.19M
P/E Ratio—
EPS$-51.32
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+4,441.8% upside
Current
$0.62
$0.62
Target
$28.25
$28.25
$22.50
$28.25 avg
$48.31
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.10M | 989.8K | 1.05M |
| Net Income | -234,853 | -218,932 | -208,731 |
| Profit Margin | -21.4% | -22.1% | -19.9% |
| EBITDA | -290,262 | -298,722 | -291,498 |
| Free Cash Flow | -192,766 | -116,937 | -167,359 |
| Rev Growth | -6.5% | +19.5% | +20.8% |
| Debt/Equity | 0.95 | 1.14 | 1.06 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |